Home > News > Fisher Scientific Expands Presence in Molecular Diagnostics
March 16th, 2006
Fisher Scientific Expands Presence in Molecular Diagnostics
Abstract:
Fisher Scientific International Inc. (NYSE: FSH) announced two transactions that will significantly enhance its capabilities in molecular diagnostics. Fisher has entered into a definitive agreement to acquire privately held Athena Diagnostics, Inc., from Behrman Capital for $283 million in cash. Simultaneous with its acquisition of Athena, Fisher has entered into an agreement to purchase 9 percent of Nanogen, Inc. (Nasdaq: NGEN) for $15 million in cash.
Source:
businesswire
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||